Ligand Pharmaceuticals Incorporated
DE ˙ DB ˙ US53220K5048
198,00 € ↑2,00 (1,02%)
2026-06-04
CENA AKCJI
SecurityDE:LGDN / Ligand Pharmaceuticals Incorporated
InstitutionState Street Corp
Latest Disclosed Ownership649,914 shares
Ownership 3.85%
State Street Corp ownership in LGDN / Ligand Pharmaceuticals Incorporated

2023-02-06 - State Street Corp has filed an SC 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 649,914 shares of Ligand Pharmaceuticals Incorporated (DE:LGDN). This represents 3.85 percent ownership of the company. In their previous filing dated 2022-02-11 , State Street Corp had reported owning 887,353 shares, indicating a decrease of -26.76 percent.

Institutional Ownership: 13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File
Date		Effective
Date		Form Prev
Shares		 Latest
Shares		 ΔShares
(Percent)		 Ownership
(Percent)		 ΔOwnership
(Percent)
2023-02-06 2023-02-06 13G/A 887,353 649,914 -26.76 3.85 -27.50
2022-02-11 2022-02-11 13G/A 1,165,390 887,353 -23.86 5.31 -26.76
2021-02-16 2021-02-16 13G 1,253,712 1,165,390 -7.04 7.25 1.54
2020-02-14 2020-02-14 13G 1,253,712 7.14

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 778,856 27,651 3.68 155,499 9.48 0.0054
2026-02-13 2025-12-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 751,205 1,845 0.25 142,030 7.00 0.0048
2025-11-14 2025-09-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 749,360 -394 -0.05 132,742 55.74 0.0046
2025-08-14 2025-06-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 749,754 22,629 3.11 85,232 11.49 0.0032
2025-05-15 2025-03-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 727,125 -16,507 -2.22 76,450 -4.05 0.0032
2025-02-14 2024-12-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 743,632 36,218 5.12 79,680 12.53 0.0031
2024-11-14 2024-09-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 707,414 18,642 2.71 70,805 22.00 0.0029
2024-08-14 2024-06-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 688,772 17,488 2.61 58,036 18.27 0.0025
2024-05-15 2024-03-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 671,284 3,000 0.45 49,071 2.81 0.0022
2024-02-14 2023-12-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 668,284 45,029 7.22 47,729 27.80 0.0023
2023-11-14 2023-09-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 623,255 10,643 1.74 37,345 -15.45 0.0021
2023-08-14 2023-06-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 612,612 -32,946 -5.10 44,169 -6.99 0.0023
2023-05-15 2023-03-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 645,558 -4,356 -0.67 47,487 9.38 0.0027
2023-05-15 2022-12-31 13F/A-99 LIGAND PHARMACEUTICALS COM NEW 53220K504 649,914 -301,404 -31.68 43,414 -47.00 0.0026
2023-05-15 2022-12-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 649,914 -301,404 43,414 0.0026
2022-11-15 2022-09-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 951,318 -132,599 -12.23 81,918 -15.29 0.0052
2022-08-15 2022-06-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 1,083,917 -7,876 -0.72 96,707 -21.26 0.0058
2022-05-16 2022-03-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 1,091,793 204,440 23.04 122,816 -10.39 0.0061
2022-02-14 2021-12-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 887,353 -30,860 -3.36 137,061 7.14 0.0065
2021-11-15 2021-09-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 918,213 58,765 6.84 127,925 13.46 0.0068
2021-08-16 2021-06-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 859,448 76,688 9.80 112,751 -5.51 0.0059
2021-07-09 2021-03-31 13F/A-1 LIGAND PHARMACEUTICALS COM NEW 53220K504 782,760 -382,630 -32.83 119,332 2.96 0.0068
2021-05-17 2021-03-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 782,760 -382,630 119,332 0.0068
2021-02-16 2020-12-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 1,165,390 193,763 19.94 115,898 25.14 0.0071
2020-11-10 2020-09-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 971,627 -38,561 -3.82 92,615 -18.03 0.0063
2020-08-14 2020-06-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 1,010,188 -242,570 -19.36 112,990 24.03 0.0082
2020-06-19 2020-03-31 13F/A-1 LIGAND PHARMACEUTICALS COM NEW 53220K504 1,252,758 -954 -0.08 91,101 -30.32 0.0080
2020-05-11 2020-03-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 1,252,758 -954 91,101 8,000.5021
2020-02-06 2019-12-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 1,253,712 -16,978 -1.34 130,750 3.37 0.0090
2019-11-14 2019-09-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 1,270,690 93,727 7.96 126,484 -5.85 0.0094
2019-08-14 2019-06-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 1,176,963 -113,545 -8.80 134,350 -17.19 0.0100
2019-05-15 2019-03-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 1,290,508 285,574 28.42 162,230 18.96 0.0127
2019-02-12 2018-12-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 1,004,934 144,823 16.84 136,370 -42.24 0.0124
2018-11-09 2018-09-30 13F LIGAND PHARMACEUTICAL Common equity shares 53220K504 860,111 -50,616 -5.56 236,084 25.13 0.0181
2018-08-14 2018-06-30 13F LIGAND PHARMACEUTICAL Common equity shares 53220K504 910,727 -39,562 -4.16 188,672 20.21 0.0158
2018-05-15 2018-03-31 13F LIGAND PHARMACEUTICAL Common equity shares 53220K504 950,289 -17,238 -1.78 156,953 18.47 0.0133
2018-02-14 2017-12-31 13F LIGAND PHARMACEUTICAL Common equity shares 53220K504 967,527 115,110 13.50 132,481 14.15 0.0107
2017-11-14 2017-09-30 13F LIGAND PHARMACEUTICAL Common equity shares 53220K504 852,417 40,785 5.03 116,055 17.79 0.0100
2017-08-14 2017-06-30 13F LIGAND PHARMACEUTICAL Common equity shares 53220K504 811,632 -38,642 -4.54 98,529 9.48 0.0087
2017-05-15 2017-03-31 13F LIGAND PHARMACEUTICAL Common equity shares 53220K504 850,274 1,281 0.15 89,995 4.32 0.0080
2017-02-09 2016-12-31 13F LIGAND PHARMACEUTICAL Common equity shares 53220K504 848,993 -22,588 -2.59 86,269 -3.01 0.0081
2017-01-13 2016-09-30 13F/A-1 LIGAND PHARMACEUTICAL Common equity shares 53220K504 871,581 134,578 18.26 88,947 1.19 0.0090
2016-11-14 2016-09-30 13F LIGAND PHARMACEUTICAL Common equity shares 53220K504 871,581 88,947
2016-08-12 2016-06-30 13F LIGAND PHARMACEUTICAL Common equity shares 53220K504 737,003 37,215 5.32 87,904 17.30 0.0094
2016-05-20 2016-03-31 13F/A-1 LIGAND PHARMACEUTICAL Common equity shares 53220K504 699,788 64,410 10.14 74,940 8.79 0.0081
2016-05-12 2016-03-31 13F LIGAND PHARMACEUTICAL Common equity shares 53220K504 699,788 74,940
2016-02-16 2015-12-31 13F LIGAND PHARMACEUTICAL Common equity shares 53220K504 635,378 44,778 7.58 68,885 36.17 0.0075
2015-11-16 2015-09-30 13F LIGAND PHARMACEUTICAL Common equity shares 53220K504 590,600 -14,127 -2.34 50,587 -17.09 0.0059
2015-08-13 2015-06-30 13F LIGAND PHARMACEUTICAL Common equity shares 53220K504 604,727 -42,609 -6.58 61,018 22.24 0.0065
2015-05-15 2015-03-31 13F LIGAND PHARMACEUTICAL Common equity shares 53220K504 647,336 -21,729 -3.25 49,917 40.22 0.0051
2015-02-11 2014-12-31 13F LIGAND PHARMACEUTICAL Common equity shares 53220K504 669,065 21,754 3.36 35,600 17.04 0.0035
2014-11-12 2014-09-30 13F/A-1 LIGAND PHARMACEUTICAL Common equity shares 53220K504 647,311 75,327 13.17 30,417 -14.64 0.0033
2014-11-10 2014-09-30 13F LIGAND PHARMACEUTICAL Common equity shares 53220K504 647,311 30,417
2014-08-12 2014-06-30 13F LIGAND PHARMACEUTICAL Common equity shares 53220K504 571,984 -17,487 -2.97 35,632 -10.12 0.0038
2014-05-15 2014-03-31 13F/A-1 LIGAND PHARMACEUTICAL Common equity shares 53220K504 589,471 -39,489 -6.28 39,646 19.82 0.0045
2014-05-13 2014-03-31 13F LIGAND PHARMACEUTICAL Common equity shares 53220K504 589,671 39,659
2014-02-06 2013-12-31 13F/A-1 LIGAND PHARMACEUTICAL Common equity shares 53220K504 628,960 -133,041 -17.46 33,087 0.32 0.0037
2014-02-06 2013-12-31 13F LIGAND PHARMACEUTICAL Common equity shares 53220K504 345,745 7,173
2013-11-12 2013-09-30 13F LIGAND PHARMACEUTICAL Common equity shares 53220K504 762,001 251,879 49.38 32,980 72.75 0.0041
2013-08-08 2013-06-30 13F LIGAND PHARMACEUTICAL Common equity shares 53220K504 510,122 510,122 19,091 0.0025
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.